An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Haematologica (Roma) 2022-12, Vol.107 (12), p.2977-2982
Hauptverfasser:	Fiedler, Walter, Montesinos, Pau, Schliemann, Christoph, Middeke, Jan, Vasu, Sumithira, Scholz, Christian W, Esteve, Jordi, Mondal, Shoubhik, Rüter, Björn, Burkard, Ute, Osswald, Annika, Blum, William
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Decitabine - therapeutic use Humans Letter to the Editor Leukemia, Myeloid, Acute - drug therapy Maximum Tolerated Dose Sialic Acid Binding Ig-like Lectin 3
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!